News

Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101

13th December 2017 / Sciad Newswire / Amyndas Pharmaceuticals, which is committed to developing innovative therapeutics for complement-mediated conditions, today announced positive preliminary results from a Phase 1 clinical trial of its C3-targeted complement inhibitor, AMY-101. The phase I which has just been completed, was a prospective, single-center, open-label, First-In-Human (FIH) clinical […]

Read More →

Press Release: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its complement C3 inhibitor AMY-101

Amyndas Pharmaceuticals, which is committed to developing innovative therapeutics for complement-mediated conditions, today announced positive preliminary results from a Phase 1 clinical trial of its C3-targeted complement inhibitor, AMY-101. The phase I which has just been completed, was a prospective, single-center, open-label, First-In-Human (FIH) clinical study, designed to assess the […]

Read More →

Study on reversing periodontitis with Cp40 features on 6 ABC Action News

The study titled “Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3” led by Dr. John Lambris and Dr. George Hajishengallis was recently featured on 6 ABC Action News. The study, which was published in the Journal of Clinical Periodontology, has provided […]

Read More →

MedicalResearch.com: Cp40 reverses periodontitis

George Hajishengallis, Thomas W. Evans Centennial Professor at the School of Dental Medicine at the University of Pennsylvania, gave an interview to MedicalResearch.com regarding the potential for Cp40 to serve as an adjunctive therapy to the management of human chronic periodontitis. He discussed a current study, the result of eight […]

Read More →

Press Release: Amyndas’ lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy

Amyndas Pharmaceuticals SA recently announced that its lead candidate, the C3 complement inhibitor AMY-101, has been granted orphan designation by the European Medicines Agency (EMA) and the U.S. FDA for the treatment of C3 glomerulopathy (C3G). Specifically, AMY-101 is the first drug to be granted an orphan drug status by […]

Read More →

Press Release: The Aplastic Anemia & MDS International Foundation supports Amyndas Pharmaceuticals’ novel complement inhibitor AMY-101

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas’ lead candidate AMY-101, as a novel treatment for paroxysmal nocturnal hemoglobinuria (PNH). The AA&MDSIF has awarded Dr. Risitano (Federico II University) and Dr. Calado (University of Sao Paolo) a grant to fund the first clinical […]

Read More →

Press Release: What’s eating the erythrocytes?

A recent press release on the Penn Medicine News Blog explains a study which “further support[s] the concept that complement inhibition at the level of C3 rather than C5 will hopefully confer better therapeutic benefits for PNH patients because it will prevent destruction of red blood cells both inside and outside of vessels.” Such a therapeutic possibility is compstatin, a C3 inhibitor drug in development that was recently licensed by Amyndas Pharmaceuticals. Clinical trials for the resulting drug candidate are set for 2015 and 2016.To read entire press release: news.pennmedicine.org

Amyndas participates in a major publication on Paroxysmal Nocturnal Hemoglobinuria (PNH)

A new review article titled ”A complement C3-targeted complement inhibitor reaching its prime for bedside intervention” by Mastellos et al., has been accepted for publication in the European Journal of Clinical Investigation. The review analyzes why complement component C3 represents an attractive target for therapeutic modulation of the complement cascade and describes in detail the optimization effort which has led to the structure-function refinement of compstatin and its novel derivatives such as AMY-101, with improved inhibitory potency, pharmacokinetic profile and efficacy in a number of clinically relevant primate models of disease. The review discusses translational challenges in complement drug discovery and peptide drug development and analyzes concerns related to systemic C3 interception; despite existing challenges AMY-101 emerges as a highly promising complement inhibitor therapeutic.